New drugs, new options on the horizon

Drug type: New HIV drug  Generic HIV drug


Trogarzo  (ibalizumab, IBA): Approved March 6 as a monoclonal antibody-entry inhibitor given by infusion. An injectable may become available later.

darunavir/cobicistat/tenofovir alfenamide/emtricitabine (DRV/COBI/TAF/FTC): The first single-tablet regimen containing a protease inhibitor is expected to be approved by July 22.

doravirine/tenofovir DF/lamivudine (doravirine/TDF/3TC): A single tablet regimen containing a non-nuke that may work in those who have developed resistance to other non-nukes; with no food restrictions. Approval expected by October 23.

fostemsavir: Attachment inhibitor. Development status unknown.

tenofovir DF/lamivudine (TDF/3TC): Expected to be available as a generic fixed-dose combination similar to Truvada.

Symfi Lo (efavirenz/tenofovir DF/lamivudine, EFV/TDF/3TC): Approved February 7 as a generic as a single-tablet regimen, similar to Atripla.


cabotegravir/rilpivirine LA: A long-acting injectable containing an INSTI and an NNRTI.

dolutegravir/lamivudine (DTG/3TC): Two-drug therapy containing an INSTI and a nuke.

Prezista (darunavir, DRV): Expected to go generic.


Atripla (efavirenz/tenofovir DF/emtricitabine, EFV/TDF/FTC): Expected to go generic.

Emtriva (emtricitabine, FTC): Expected to go generic.